PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-25.63%
Negative ROE while Biotechnology median is -12.64%. Seth Klarman would investigate if capital structure or industry issues are at play.
-11.45%
Negative ROA while Biotechnology median is -12.17%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-14.18%
Negative ROCE while Biotechnology median is -12.85%. Seth Klarman would investigate whether a turnaround is viable.
-145.68%
Negative gross margin while Biotechnology median is 56.62%. Seth Klarman would check if the firm is selling below cost.
-12769.14%
Negative operating margin while Biotechnology median is -167.60%. Seth Klarman would look for a path to operational turnaround.
-11511.11%
Negative net margin while Biotechnology median is -144.96%. Seth Klarman would see if cost cuts or revenue growth can fix losses.